Background
Methods
Literature searching strategy
1. PubMed |
1. Hepatitis C[Mesh] OR HCV 2. HCC OR “hepatocellular carcinoma” 3. SVR OR “sustained virologic response” 4. Mortality (#1 AND #2) OR (#1 AND #3) OR (#1 AND #4) - > removed duplicated articles |
2. Embase |
1. (hepatitis C or hcv).mp 2. (hcc or hepatocellular carcinoma).mp 3. (svr or sustained virologic reponse).mp 4. mortality After accumulation of (1 and 2), (1 and 3), and (1 and 4), and then removed duplicated articles |
3. Cochrane library |
1. Hepatitis C OR HCV 2. HCC OR “hepatocellular carcinoma” 3. SVR OR “sustained virologic response” 4. Mortality (#1 AND #2) OR (#1 AND #3) OR (#1 AND #4) - > removed duplicated articles |
Selection criteria
Methodological quality
Primary and modifier-based analyses
Statistics
Results
Identification of relevant studies
Characteristics of included studies
Topic | Number of enrolled studies and population | Study format | Nationality | Age | Follow-up duration | Treatment regimen | Histology |
---|---|---|---|---|---|---|---|
Topic 1 | 25 studies (9691 treated vs. 6010 control) | 3 RCTs 8 prospective cohort studies 14 retrospective cohort studies | 15 Western population-based studies 10 Asian population-based studies | 37 to 61 years (median) | 32 months to 10 years (mean) | IFN-based regimens with or without RBV, except 4 studies with a PegIFN-based regimen | 10 studies exclusively assessing LC patients) |
Topic 2 | 17 studies (9868 treated vs. 4700 controls) | 1 RCT 5 prospective cohort studies 11 retrospective cohort studies | 8 Western population-based studies 9 Asian population-based studies | 37 to 61 years (median) | 55 months to 11.5 years (median) | IFN-based regimen with or without RBV, except 3 studies with a PegIFN-based regimen | 3 studies exclusively assessing LC patients |
Topic 3 | 13 studies (8671 treated vs. 2831 controls) | 5 prospective cohort studies 8 retrospective cohort studies | 5 Western population-based studies 8 Asian population-based studies | 37 to 61 years (median) | 55 months to 11.5 years (median) | IFN-based regimen with or without RBV, except 2 studies with a PegIFN-based regimen | 4 studies exclusively assessing LC patients |
Topic 4 | 35 studies (14756 patients with SVR vs. 12741 patients with no SVR) | 1 RCT 8 prospective cohort studies 26 retrospective cohort studies | 17 Western population-based studies 17 Asian population-based studies 1 Saudi Arabia and Egypt population-based study | 37 to 64 years (median) | 2.1 (median) to 10 years (mean) | 20 studies with PegIFN-based regimen 15 studies with IFN-based regimen | 9 studies exclusively assessing LC patients |
Topic 5 | 22 studies (12440 patients with SVR vs. 18980 patients with no SVR) | 4 prospective cohort studies 18 retrospective cohort studies | 12 Western population-based studies 9 Asian population-based studies 1 Saudi Arabia and Egypt population-based study | 41.8 to 64 years (mean) | 2.1 to 11.5 years (median) | 11 studies with PegIFN-based regimen 11 studies with IFN-based regimen | 3 studies exclusively assessing LC patients |
Topic 6 | 23 studies (5148 patients with SVR vs. 10356 patients with no SVR) | 7 prospective cohort studies 16 retrospective cohort studies | 14 Western population-based studies 9 Asian population-based studies | 41.8 to 64 (mean) | 2.1 to 11.5 years (median) | 12 studies with PegIFN-based regimen 11 studies with IFN-based regimen | 6 studies exclusively assessing LC patients |
Study | Nationality | Age | Duration of follow up | Study format | Genotype | NOS | Treatment | HCC/Total treatment | HCC/Control | Histology |
---|---|---|---|---|---|---|---|---|---|---|
Mazella G et al. (1996) [23] | Italy | Tx: 53, control: 54 (mean) | mean 32 months | P | unknown | 7 | IFN-α or lymphoblastoid | 5/193 | 9/92 | Child A LC |
Bruno S et al.(1997) [24] | Italy | Tx 56, control: 59 (mean) | median 68 months | P | 62% type 1b | 7 | IFN-α | 6/83 | 16/80 | LC (mainly Child A) |
Fattovich G et al. (1997) [25] | Italy | Tx: 53, control: 57 (mean) | mean 60 months | R | unknown | 8 | IFN-α | 7/193 | 16/136 | LC |
Serfaty L et al. (1998) [26] | France | Tx: 55, control: 56 (mean) | median 40 months | P | 48% 1b | 7 | IFN-α | 2/59 | 9/44 | Knodell 10 (mean) |
Benvegnù L et al.(1998) [27] | Italy | Tx: 56.7, control: 59.5 (mean) | mean 71.5 months | P | unknown | 8 | IFN | 4/75 | 20/77 | Child A LC |
International Interferon-α Hepatocellular Carcinoma Study Group (1998) [28] | Italy and Argentina | 54 (median) | 36 months | R | unknown | 7 | IFN-α or lymphoblastoid | 21/232 | 48/259 | unknown |
Imai Y et al.(1998) [29] | Japan | unknown | Tx: 47.6, control: 46.8 (median) | R | unknown | 7 | IFN-α | 28/419 | 19/144 | F3,4: 37% in Tx, 53% in control |
Yoshida H et al. (1999) [30] | Japan | Tx: 49.5, control: 53.6 (mean) | median 4.3 years | R | 70.3% type 1 | 7 | IFN-α or IFN-β or combination | 89/2400 | 59/490 | F3,4: 33.1% in Tx, 33.8% in control |
Okanoue T et al. (1999) [31] | Japan | 42.6–57.6 (mean) | mean 39.5–67.1 months | R | unknown | 7 | IFN-α or lymphoblastoid | 52/1148 | 22/55 | F3,4: 34% in Tx, F4: 100% in control |
Valla DC et al. (1999) [32] | France | Tx: 57, control: 56 (mean) | mean 160 weeks | RCT | unknown | IFN-α | 5/47 | 9/52 | compensated LC | |
Ikeda K et al. (2001) [33] | Japan | 57 (median) | median 7.6 years | R | unknown | 7 | IFN-α or IFN-β | 32/113 | 271/581 | LC |
Gramenzi A et al. (2001) [34] | Italy | Tx: 57.9, control: 58.1 (mean) | median 55–58 months | P | unknown | 7 | IFN-α | 6/72 | 19/72 | LC (mainly Child A) |
Nishiguchi S et al. (2001) [35] | Japan | Tx: 54.7, control: 57.3 (mean) | mean 8.2 years | RCT | 75.6% type 2 | IFN-α | 12/45 | 33/45 | unknown | |
Testino G et al. (2002) [16] | Italy | Tx: 55.3, control: 56.8 (mean) | mean 95.4 months | R | 55% type 1b, 45% type 2 | 8 | IFN-α | 12/51 | 24/71 | Child A LC |
Coverdale SA et al. (2004) [36] | Australia | Tx: 37, control: 38 (median) | median 9 years | P | 39.6% type 1 | 7 | IFN-α | 26/384 | 7/71 | Scheuer fibrosis score 2 |
Azzaroli F et al. (2004) [37] | Italy | 55.1 (mean) | 5 years | RCT | 64.4% type 1b | IFN-α with RBV | 2/71 | 9/30 | LC | |
Shiratori Y et al. (2005) [38] | Japan | Tx: 57, control: 61 (median) | median 6.8 years | P | 71.9% type 1b | 8 | IFN-α or lymphoblastoid | 84/271 | 35/74 | unknown |
Yu ML et al. (2006) [39] | Taiwan | Tx: 46.9, control: 43.6 (mean) | mean 5.18–5.15 years | R | 46.2% type 1 | 8 | IFN-α with or without RBV | 51/1057 | 54/562 | LC 15.6% in Tx, 12.1% in control |
Sinn DH et al. (2008) [40] | Korea | 48.4–58.2 (mean) | median 55.2 months | R | 48.6% type 2 | 7 | IFN/PegIFN with or without RBV | 14/490 | 122/647 | F3,4: 49% in Tx, F4: 33% in control |
Di Martino V et al. (2011) [41] | France | unknown | median 59 months | R | 57.9% type 1 | 7 | IFN with or without RBV, or PegIFN with RBV | 9/184 | 5/184 | 55.5% F2 or greater |
Tateyama M et al. (2011) [42] | Japan | 57 (median) | mean 8.2 years | R | 72.1% type 1b | 8 | IFN/PegIFN with or without RBV | 110/373 | 63/334 | F3,4: 34.1% |
Maruoka D et al. (2012) [43] | Japan | 50.4–54 (mean) | mean 9.9 years | R | 73.6% type 1 | 8 | IFN-α/IFN-β with or without RBV | 85/577 | 35/144 | F3,4: 24.3% in Tx, F4: 43.1% in control |
Cozen ML et al. (2013) [44] | US | 50.98 (mean) | mean 10 years | R | 68.7% type 1 | 8 | IFN-α with or without RBV | 11/159 | 9/199 | F3,4: 19% (30.2% in Tx, 10.1% in control) |
Aleman S et al. (2013) [45] | Sweden | 51 (mean) | mean 5.3 years | R | 50% type 1 | 8 | PegIFN with RBV | 32/303 | 14/48 | LC |
Cozen ML et al. (2016) [46] | US | 51.4 (mean) | mean 8.5 years | P | 71.6% type 1 or 4 | 8 | IFN-α with RBV | 43/692 | 84/1519 | LC 15.8% in Tx, 5.3% in control |
Study | Nationality | Age | Duration of follow up | Study format | Genotype | NOS | Treatment | Death/Total treatment | Death/Control | Histology |
---|---|---|---|---|---|---|---|---|---|---|
Benvegnù L et al. (1998) [27] | Italy | Tx: 56.7, control: 59.5 (mean) | mean 71.5 months | P | unknown | 8 | IFN |
a3/75 |
a15/77 | Child A LC |
Ikeda K et al. (2001) [33] | Japan | 57 (median) | median 7.6 years | R | unknown | 7 | IFN-α or IFN-β | 20/113 a12/113 | 266/581 a124/581 | LC |
Gramenzi A et al. (2001) [34] | Italy | Tx: 57.9, control: 58.1 (mean) | median 55–58 months | P | unknown | 7 | IFN-α |
a7/72 | 9/72 a8/72 | LC (mainly Child A) |
Nishiguchi S et al. (2001) [35] | Japan | Tx: 54.7, control: 57.3 (mean) | mean 8.2 years | RCT | 75.6% type 2 | IFN-α | 5/45 | 26/45 | unknown | |
Testino G et al. (2002) [16] | Italy | Tx: 55.3, control: 56.8 (mean) | mean 95.4 months | R | 55% type 1b, 45% type 2 | 8 | IFN-α | 1/51 | 9/71 | Child A LC |
Yosida H et al. (2002) [47] | Japan | Tx: 49.5, control: 54.6 (mean) | mean 5.4 years | R | unknown | 8 | IFN-α or IFN-β | 56/2430 a35/2430 | 30/459 a23/459 | F3,4: 32.2% in Tx, 31.6% in control, 26.3% in SVR, 35.2% in no SVR |
Imazeki F et al. (2003) [48] | Japan | Tx: 49.2, control: 53.1 (mean) | mean 8.2 years | R | 73.9% type 1 | 8 | IFN-α or IFN-β | 33/355 a19/355 | 15/104 a12/104 | F3,4: 26.7% in Tx, 29.8% in control, |
Coverdale SA et al. (2004) [36] | Australia | Tx: 37, control: 38 (median) | median 9 years | P | 39.6% type 1 | 7 | IFN-α |
a36/384 |
a12/71 | Scheuer fibrosis score 2 |
Kasahara A et al. (2004) [17] | Japan | Tx: 53, control: 54 (median) | mean 6 years | R | unknown | 8 | IFN | 101/2698 a69/2698 | 52/256 a42/256 | F3,4: 38.7% in Tx, 48% in control, 28.6% in SVR, 43% in no SVR |
Shiratori Y et al. (2005) [38] | Japan | Tx: 57, control: 61 (median) | median 6.8 years | P | 71.9% type 1b | 8 | IFN-α or lymphoblastoid | 45/271 a32/271 | 24/74 a19/74 | unknown |
Yu ML et al. (2006) [39] | Taiwan | Tx: 46.9, control: 43.6 (mean) | mean 5.18–5.15 years | R | 46.2% type 1 | 8 | IFN-α with or without RBV | 16/1057 a14/1057 | 12/562 a10/562 | LC 15.6% in Tx, 12.1% in control |
Di Martino V et al. (2011) [41] | France | unknown | median 59 months | R | 57.9% type 1 | 7 | IFN with or without RBV, or PegIFN with RBV | 9/184 a5/184 | 20/194 a4/184 | 55.5% F2 or greater |
Yamasaki K et al. (2012) [49] | Japan | 60.9 (mean) | median 11.5 years | P | 59.9% type 1b | 7 | IFN-α or β or lymphoblastoid with or without RBV | 25/152 a6/152 | 90/199 a32/199 | unknown |
Maruoka D et al. (2012) [43] | Japan | 50.4–54 (mean) | mean 9.9 years | R | 73.6% type 1 | 8 | IFN-α/IFN-β with or without RBV | 84/577 a52/577 | 37/144 a30/144 | F3,4: 24.3% in Tx, F4: 43.1% in control |
Cozen ML et al. (2013) [44] | US | 50.98 (mean) | mean 10 years | R | 68.7% type 1 | 8 | IFN-α with or without RBV | 31/159 | 47/199 | F3,4: 19% (30.2% in Tx, 10.1% in control) |
Aleman S et al. (2013) [45] | Sweden | 51 (mean) | mean 5.3 years | R | 50% type 1 | 8 | PegIFN with RBV | 59/303 a39/303 | 18/48 a16/48 | LC |
Kutala BK et al. (2015) [50] | France | 50 (median) | median 5.5 years | R | 55.7% type 1 | 8 | IFN/PegIFN with or without RBV | 30/325 | 19/102 | F3,4: 100% |
Cozen ML et al. (2016) [46] | US | 51.4 (mean) | mean 8.5 years | P | 71.6% type 1 or 4 | 8 | IFN-α with RBV | 112/692 | 488/1519 | LC 15.8% in Tx, 5.3% in control |
Study | Nationality | Age | Duration of follow up | Study format | Genotype | NOS | Treatment | HCC/Total SVR | HCC/No SVR | Histology |
---|---|---|---|---|---|---|---|---|---|---|
Nishiguchi S et al. (1995) [51] | Japan | Tx: 54.7, control: 57.3 (mean) | 2–7 years | RCT | 75.6% type 2 | IFN-α | 0/7 | 2/38 | HAI 11.7 in Tx, 11.8 in control (mean) | |
Tanaka K et al. (1998) [52] | Japan | SVR: 47.7, no SVR: 51 (mean) | about 40 months | P | unknown | 7 | lymphoblastoid IFN | 0/8 | 10/47 | LC |
Yoshida H et al. (1999) [30] | Japan | Tx: 49.5, control: 53.6 (mean) | median 4.3 years | R | 70.3% type 1 | 7 | IFN-α or IFN-β or combination | 10/789 | 79/1611 | F3,4: 33.1% in Tx, 33.8% in control |
Testino G et al. (2002) [16] | Italy | Tx: 55.3, control: 56.8 (mean) | mean 95.4 months | R | 55% type 1b, 45% type 2 | 8 | IFN-α | 3/11 | 12/40 | Child A LC |
Okanoue T et al. (2002) [53] | Japan | Tx: 50.4, control: 58.1 (mean) | Mean 5.6 years | R | unknown | 7 | IFN-α or lymphoblastoid | 4/426 | 110/994 | F3,4: 20.9% in SVR, 34.4% in control |
Coverdale SA et al. (2004) [36] | Australia | Tx: 37, control: 38 (median) | median 9 years | P | 39.6% type 1 | 7 | IFN-α | 1/50 | 25/334 | Scheuer fibrosis score 2 |
Shiratori Y et al. (2005) [38] | Japan | Tx: 57, control: 61 (median) | median 6.8 years | P | 71.9% type 1b | 8 | IFN-α or lymphoblastoid | 11/64 | 73/207 | unknown |
Yu ML et al. (2006) [39] | Taiwan | Tx: 46.9, control: 43.6 (mean) | mean 5.18–5.15 years | R | 46.2% type 1 | 8 | IFN-α with or without RBV | 12/715 | 39/342 | LC 15.6% in Tx, 12.1% in control |
Pradat P et al. (2007) [54] | Europe | 45–47 (mean) | 5–7 years | P | 49.2% type 1 | 6 | IFN/PegIFN with or without RBV | 0/91 | 17/266 | unknown |
Braks RE et al. (2007) [55] | France | 54.1 (mean) | mean 7.7 years | R | 61.1% type 1 | 8 | IFN-α with or without RBV, or PegIFN with RBV | 1/37 | 24/76 | Child A LC |
Bruno S et al. (2007) [56] | Italy | 54.7 (mean) | Mean 96.1 months | R | 71.8% type 1 | 8 | IFN-α | 7/124 | 122/759 | Child A LC |
Hasegawa E et al. (2007) [57] | Japan | 56 (median) | median 4.6 years | R | 65% 2a | 7 | IFN-α,β/lymphoblastoid with or without RBV | 3/48 | 16/57 | LC |
Veldt BJ et al. (2007) [58] | Europe and Canada | 48 (median) | median 2.1 years | R | 59% type 1 | 8 | IFN/PegIFN with or without RBV | 3/142 | 32/337 | Ishak 4–6 |
Floreani A et al. (2008) [59] | Italy | 44.5–55.7 (mean) | mean 23.4–25.2 months | R | 41.3% type 1 | 7 | PegIFN with RBV | 0/40 | 5/38 | unknown |
Sinn DH et al. (2008) [40] | Korea | 48.4–58.2 (mean) | median 55.2 months | R | 48.6% type 2 | 7 | IFN/PegIFN with or without RBV | 4/296 | 10/194 | F3,4: 49% in Tx, F4: 33% in control |
Kurokawa M et al. (2009) [60] | Japan | 55.8 (mean) | median 36.5 months | R | 72.9% type 1 | 7 | IFN-α with RBV | 4/139 | 21/264 | F3,4: 31.3% |
Asahina Y et al. (2010) [61] | Japan | 55.4 (mean) | mean 7.5 years | R | 69.6% type 1b | 8 | IFN-α,β with or without RBV, or PegIFN with RBV | 22/686 | 149/1356 | F3,4: 25.2% |
Kawamura Y et al. (2010) [62] | Japan | 50 (median) | median 6.7 years | R | unknown | 8 | IFN-α,β with or without RBV | 12/1081 | 61/977 | F1,2: 93.1% |
Cardoso AC et al. (2010) [63] | France | 55 (mean) | median 3.5 years | R | 60% type 1 | 7 | IFN/PegIFN with or without RBV | 6/103 | 40/204 | F3,4: 100% |
Morgan TR et al. (2010) [64] | US | 48.6–49.6 (mean) | median 79–96 months | P | 87.2% type 1 | 8 | PegIFN with or without RBV | 2/140 | 33/386 | F3,4: 100% |
Di Martino V et al. (2011) [41] | France | unknown | median 59 months | R | 57.9% type 1 | 7 | IFN with or without RBV, or PegIFN with RBV | 1/59 | 8/125 | 55.5% F2 or greater |
Velosa J et al. (2011) [65] | Portugal | 51.7 (mean) | mean 6.4 years | R | 61% type 1 | 7 | IFN/PegIFN with or without RBV | 1/39 | 20/91 | compensated LC |
Iacobellis A et al. (2011) [66] | Italy | 59–62 (mean) | mean 51 months | P | 57.3% type 1 | 7 | PegIFN with RBV | 5/24 | 11/51 | decompensated LC |
Hung CH et al. (2011) [67] | Taiwan | 53 (median) | median 4.3 years | R | 49% type 1 | 7 | IFN/PegIFN with or without RBV | 33/1027 | 54/443 | unknown |
Takahashi H et al. (2011) [68] | Japan | 55.4 (mean) | Mean 52 months | R | 74.9% type 1b | 7 | IFN-α,β/PegIFN with RBV | 1/89 | 12/114 | F3,4: 23.2% |
Backus LI et al. (2011) [69] | US | 51–53 (mean) | median 3.8 years | R | 72.1% type 1 | 6 | PegIFN with RBV | 223/7434 | 283/1440 | 13% LC |
Tateyama M et al. (2011) [42] | Japan | 57 (median) | mean 8.2 years | R | 72.1% type 1b | 8 | IFN/PegIFN with or without RBV | 3/139 | 44/234 | F3,4: 34.1% |
Osaki Y et al. (2012) [70] | Japan | 59 (median) | median 4.1 years | R | 59.9% type 1 | 7 | IFN/PegIFN with RBV | 1/185 | 22/197 | unknown |
van der Meer AJ et al. (2012) [71] | Europe and Canada | 48 (mean) | median 8.4 years | R | 68% type 1 | 8 | IFN/PegIFN with or without RBV | 7/125 | 76/405 | Ishak 4–6 |
Maruoka D et al. (2012) [43] | Japan | 50.4–54 (mean) | mean 9.9 years | R | 73.6% type 1 | 8 | IFN-α/IFN-β with or without RBV | 5/221 | 80/356 | F3,4: 24.3% in Tx, F4: 43.1% in control |
Cozen ML et al. (2013) [44] | US | 50.98 (mean) | mean 10 years | R | 68.7% type 1 | 8 | IFN-α with or without RBV | 2/69 | 9/90 | F3,4: 19% (30.2% in Tx, 10.1% in control) |
Alfaleh FZ et al. (2013) [72] | Saudi Arabia, Egypt | 48 (mean) | mean 63.8 months | P | 30.6% type 4 | 8 | PegIFN with or without RBV | 0/62 | 4/95 | F3,4: 24.6% (27.1% in SVR, 31.1% in no SVR) |
Aleman S et al. (2013) [45] | Sweden | 51 (mean) | mean 5.3 years | R | 50% type 1 | 8 | PegIFN with RBV | 6/110 | 26/193 | LC |
Di Marco V et al. (2016) [73] | Italy | 58 (mean) | median 7.6 years | P | 83.4% type 1 | 8 | PegIFN with RBV | 7/108 | 92/336 | compensated LC |
Ikezaki H et al. (2016) [74] | Japan | 60–64 (median) | median 2.8 years | R | 52.7% in type 1 | 7 | IFN- β with RBV | 2/68 | 7/44 | F3,4: 30.9% in SVR, 72.7% in no SVR |
Study | Nationality | Age | Duration of follow up | Study format | Genotype | NOS | Treatment | Death/Total SVR | Death/No SVR | Histology |
---|---|---|---|---|---|---|---|---|---|---|
Yosida H et al. (2002) [47] | Japan | Tx: 49.5, control: 54.6 (mean) | mean 5.4 years | R | unknown | 8 | IFN-α or IFN-β |
a7/817 |
a49/1613 | F3,4: 32.2% in Tx, 31.6% in control, 26.3% in SVR, 35.2% in no SVR |
Okanoue T et al. (2002) [53] | Japan | Tx: 50.4, control: 58.1 (mean) | Mean 5.6 years | R | unknown | 7 | IFN-α or lymphoblastoid | 2/426 a0/426 | 47/994 a34/994 | F3,4: 20.9% in SVR, 34.4% in control |
Imazeki F et al. (2003) [48] | Japan | Tx: 49.2, control: 53.1 (mean) | mean 8.2 years | R | 73.9% type 1 | 8 | IFN-α or IFN-β | 4/116 a1/116 | 29/239 a18/239 | F3,4: 26.7% in Tx, 29.8% in control |
Coverdale SA et al. (2004) [36] | Australia | Tx: 37, control: 38 (median) | median 9 years | P | 39.6% type 1 | 7 | IFN-α |
a1/50 |
a35/334 | Scheuer fibrosis score 2 |
Kasahara A et al. (2004) [17] | Japan | Tx: 53, control: 54 (median) | mean 6 years | R | unknown | 8 | IFN | 7/738 a1/738 | 94/1930 a68/1930 | F3,4: 38.7% in Tx, 48% in control, 28.6% in SVR, 43% in no SVR |
Shiratori Y et al. (2005) [38] | Japan | Tx: 57, control: 61 (median) | median 6.8 years | P | 71.9% type 1b | 8 | IFN-α or lymphoblastoid | 1/64 a0/64 | 44/207 a32/207 | unknown |
Yu ML et al. (2006) [39] | Taiwan | Tx: 46.9, control: 43.6 (mean) | mean 5.18–5.15 years | R | 46.2% type 1 | 8 | IFN-α with or without RBV | 4/715 a3/715 | 12/342 a11/342 | LC 15.6% in Tx, 12.1% in control |
Arase Y et al. (2007) [75] | Japan | SVR: 63, no SVR: 64 (mean) | mean 7.4 years | R | 60.4% type 1b | 8 | IFN-α/β with or without RBV | 9/140 a2/140 | 44/360 a32/360 | F3,4: 14.5 in SVR, 27.5 in no SVR |
Bruno S et al. (2007) [56] | Italy | 54.7 (mean) | Mean 96.1 months | R | 71.8% type 1 | 8 | IFN-α | 6/124 a2/120 | 114/759 a83/728 | Child A LC |
Veldt BJ et al. (2007) [58] | Europe and Canada | 48 (median) | median 2.1 years | R | 59% type 1 | 8 | IFN/PegIFN with or without RBV | 2/142 a1/142 | 24/337 a19/337 | Ishak 4–6 |
Cardoso AC et al. (2010) [63] | France | 55 (mean) | median 3.5 years | R | 60% type 1 | 7 | IFN/PegIFN with or without RBV |
a3/103 |
a18/204 | F3,4: 100% |
Morgan TR et al. (2010) [64] | US | 48.6–49.6 (mean) | median 79–96 months | P | 87.2% type 1 | 8 | PegIFN with or without RBV |
a1/140 |
a23/386 | F3,4: 100% |
Innes HA et al. (2011) [76] | UK | 41.8 (mean) | mean 5.3 years | R | 35.6% type 1 | 8 | IFN/PegIFN with or without RBV | 13/560 a5/560 | 75/655 a50/655 | 85.8% no LC |
Di Martino V et al. (2011) [41] | France | unknown | median 59 months | R | 57.9% type 1 | 7 | IFN with or without RBV, or PegIFN with RBV | 0/59 a0/59 | 9/125 a5/125 | 55.5% F2 or greater |
Velosa J et al. (2011) [65] | Portugal | 51.7 (mean) | mean 6.4 years | R | 61% type 1 | 7 | IFN/PegIFN with or without RBV |
a0/39 |
a15/91 | compensated LC |
Iacobellis A et al. (2011) [66] | Italy | 59–62 (mean) | mean 51 months | P | 57.3% type 1 | 7 | PegIFN with RBV |
a2/24 |
a23/51 | decompensated LC |
Backus LI et al. (2011) [69] | US | 51–53 (mean) | median 3.8 years | R | 72.1% type 1 | 6 | PegIFN with RBV | 525/7434 | 1440/9430 | 13% LC |
Yamasaki K et al. (2012) [49] | Japan | 60.9 (mean) | median 11.5 years | P | 59.9% type 1b | 7 | IFN-α or β or lymphoblastoid with or without RBV | 9/72 a1/72 | 16/80 a5/80 | unknown |
van der Meer AJ et al. (2012) [71] | Europe and Canada | 48 (mean) | median 8.4 years | R | 68% type 1 | 8 | IFN/PegIFN with or without RBV | 13/125 a3/125 | 100/405 a103/405 | Ishak 4–6 |
Maruoka D et al. (2012) [43] | Japan | 50.4–54 (mean) | mean 9.9 years | R | 73.6% type 1 | 8 | IFN-α/IFN-β with or without RBV | 10/221 a2/221 | 74/356 a50/356 | F3,4: 24.3% in Tx, F4: 43.1% in control |
Cozen ML et al. (2013) [44] | US | 50.98 (mean) | mean 10 years | R | 68.7% type 1 | 8 | IFN-α with or without RBV | 6/69 | 25/90 | F3,4: 19% (30.2% in Tx, 10.1% in control) |
Alfaleh FZ et al. (2013) [72] | Saudi Arabia, Egypt | 48 (mean) | mean 63.8 months | P | 30.6% type 4 | 8 | PegIFN with or without RBV | 0/62 a0/62 | 4/95 a8/95 | F3,4: 24.6% (27.1% in SVR, 31.1% in no SVR) |
Aleman S et al. (2013) [45] | Sweden | 51 (mean) | mean 5.3 years | R | 50% type 1 | 8 | PegIFN with RBV | 11/110 a4/110 | 48/193 a35/193 | LC |
Singal AG et al. (2013) [77] | US | 48 (median) | median 36–72 months | R | 68.6% type 1 | 7 | PegIFN with RBV | 2/83 | 41/159 | 17.3% LC |
Dieperink E et al. (2014) [78] | US | 51.4 (mean) | median 7.5 years | R | 70% type 1 | 8 | IFN/PegIFN with or without RBV | 19/222 a6/222 | 81/314 a56/314 | F3,4: 54.5% (41.3% in SVR, 64.7% in no SVR) |
Kutala BK et al. (2015) [50] | France | 50 (median) | median 5.5 years | R | 55.7% type 1 | 8 | IFN/PegIFN with or without RBV | 3/104 | 27/221 | F3,4: 100% |
Di Marco V et al. (2016) [73] | Italy | 58 (mean) | median 7.6 years | P | 83.4% type 1 | 8 | PegIFN with RBV |
a8/108 |
a98/336 | compensated LC |
Methodological quality
Efficacy of antiviral treatment on the development of HCC in chronic hepatitis C patients
Efficacy of antiviral treatment on All-cause mortality in patients with chronic hepatitis C
Efficacy of antiviral treatment on liver-specific mortality in chronic hepatitis C patients
Efficacy of SVR on the development of HCC in patients with chronic hepatitis C
Efficacy of SVR on all-cause mortality in patients with chronic hepatitis C
Efficacy of SVR on liver-specific mortality in chronic hepatitis C patients
Modifier | Coefficient | Standard error |
P value |
---|---|---|---|
NOS (topic 1) | NOS 8: 1.203 NOS 7: 0.501 | 0.565 0.561 | 0.033 0.372 Q: 7.24, df: 2, P = 0.027 |
Follow-up duration (topic 3) | 1.140 | 0.542 | 0.036 |
NOS (topic 3) | NOS 8: −0.659 | 0.302 | 0.029 |
NOS (topic 5) | NOS 8: −0.540 NOS 7: −0.544 | 0.209 0.322 | 0.010 0.091 Q: 7.03, df: 2, P = 0.030 |